Trials / Unknown
UnknownNCT01849042
Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease
A Multicenter, Randomized, Open-label, Prospective Study to Estimate the add-on Effects of Memantine as Ebixa Oral Pump on Language in Moderate to Severe Alzheimer's Disease Patients Already Receiving Donepezil.
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 188 (estimated)
- Sponsor
- Konkuk University Medical Center · Academic / Other
- Sex
- All
- Age
- 50 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the pharmacological efficacy on language capability and compliance with combination of new Ebixa oral pump and donepezil compared to donepezil only in patients with probable Alzheimer's disease. Primary objective is to evaluate the efficacy of memantine on language capability in moderate to severe Alzheimer's disease patients who are taking stable donepezil treatment.Secondary objectives are to evaluate the efficacy of maintain on cognitive function and disease progression with K-MMSE, NPI, ROSA, and SIB-short form in probable AD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ebixa | add-on of Ebixa oral pump already receiving donepezil with stable dosage |
| DRUG | donepezil |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2014-08-01
- Completion
- 2015-08-01
- First posted
- 2013-05-08
- Last updated
- 2014-08-13
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01849042. Inclusion in this directory is not an endorsement.